nevirapine has been researched along with Insulin Resistance in 10 studies
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.
nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.
Insulin Resistance: Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of this cross-sectional observational ('real-world') study was to investigate the effect of three HAART regimens plus stable nevirapine therapy on morphological and metabolic components of lipodystrophy in HIV-infected patients." | 7.77 | Morphological and metabolic components of lipodystrophy in various nevirapine-based highly active antiretroviral therapy (HAART) regimens: a cross-sectional, observational study. ( Adorni, F; Bagni, P; Carli, F; Garlassi, E; Guaraldi, G; Luzi, K; Menozzi, M; Orlando, G; Stentarelli, C; Zona, S, 2011) |
| "The objective of this cross-sectional observational ('real-world') study was to investigate the effect of three HAART regimens plus stable nevirapine therapy on morphological and metabolic components of lipodystrophy in HIV-infected patients." | 3.77 | Morphological and metabolic components of lipodystrophy in various nevirapine-based highly active antiretroviral therapy (HAART) regimens: a cross-sectional, observational study. ( Adorni, F; Bagni, P; Carli, F; Garlassi, E; Guaraldi, G; Luzi, K; Menozzi, M; Orlando, G; Stentarelli, C; Zona, S, 2011) |
| "Lipodystrophy was evaluated by clinical examination and morphological measurements." | 2.71 | Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. ( Crespo, M; Ferrer, E; Fisac, C; Fumero, E; Gatell, JM; Podzamczer, D; Ribera, E; Roson, B; Virgili, N, 2005) |
| "Insulin sensitivity was evaluated by the HOMA model assessment." | 1.32 | Serum adiponectin and metabolic parameters in HIV-1-infected patients after substitution of nevirapine for protease inhibitors. ( Bour, JB; Brindisi, MC; Buisson, M; Duong, M; Duvillard, L; Galland, F; Gambert, P; Guiguet, M; Masson, D; Petit, JM; Portier, H; Vergès, B, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (20.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jao, J | 1 |
| Sun, S | 1 |
| Bonner, LB | 1 |
| Legbedze, J | 1 |
| Mmasa, KN | 1 |
| Makhema, J | 1 |
| Mmalane, M | 1 |
| Kgole, S | 1 |
| Masasa, G | 1 |
| Moyo, S | 1 |
| Gerschenson, M | 1 |
| Mohammed, T | 1 |
| Abrams, EJ | 2 |
| Kurland, IJ | 1 |
| Geffner, ME | 1 |
| Powis, KM | 1 |
| Kiage, JN | 1 |
| Heimburger, DC | 1 |
| Nyirenda, CK | 1 |
| Wellons, MF | 1 |
| Bagchi, S | 1 |
| Chi, BH | 1 |
| Koethe, JR | 1 |
| Arnett, DK | 1 |
| Kabagambe, EK | 1 |
| Guaraldi, G | 1 |
| Zona, S | 1 |
| Orlando, G | 1 |
| Carli, F | 1 |
| Stentarelli, C | 1 |
| Luzi, K | 1 |
| Garlassi, E | 1 |
| Menozzi, M | 1 |
| Bagni, P | 1 |
| Adorni, F | 1 |
| Arpadi, S | 1 |
| Shiau, S | 1 |
| Strehlau, R | 1 |
| Martens, L | 1 |
| Patel, F | 1 |
| Coovadia, A | 1 |
| Kuhn, L | 1 |
| Tebas, P | 1 |
| Yarasheski, K | 1 |
| Henry, K | 1 |
| Claxton, S | 1 |
| Kane, E | 1 |
| Bordenave, B | 1 |
| Klebert, M | 1 |
| Powderly, WG | 1 |
| Petit, JM | 1 |
| Duong, M | 1 |
| Masson, D | 1 |
| Buisson, M | 1 |
| Duvillard, L | 1 |
| Bour, JB | 1 |
| Brindisi, MC | 1 |
| Galland, F | 1 |
| Guiguet, M | 1 |
| Gambert, P | 1 |
| Portier, H | 1 |
| Vergès, B | 1 |
| Fisac, C | 1 |
| Fumero, E | 1 |
| Crespo, M | 1 |
| Roson, B | 1 |
| Ferrer, E | 1 |
| Virgili, N | 1 |
| Ribera, E | 1 |
| Gatell, JM | 1 |
| Podzamczer, D | 1 |
| Dieleman, JP | 1 |
| Hillebrand-Haverkort, ME | 1 |
| van der Ende, ME | 1 |
| Sturkenboom, MC | 1 |
| Lange, JM | 1 |
| Stricker, BH | 1 |
| Carr, A | 1 |
| Hudson, J | 1 |
| Chuah, J | 1 |
| Mallal, S | 1 |
| Law, M | 1 |
| Hoy, J | 1 |
| Doong, N | 1 |
| French, M | 1 |
| Smith, D | 1 |
| Cooper, DA | 1 |
5 trials available for nevirapine and Insulin Resistance
| Article | Year |
|---|---|
Lower Insulin Sensitivity in Newborns With In Utero HIV and Antiretroviral Exposure Who Are Uninfected in Botswana.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Botswana; Female; HIV Infections; Humans; Infant; Infant, N | 2022 |
Metabolic abnormalities and body composition of HIV-infected children on Lopinavir or Nevirapine-based antiretroviral therapy.
Topics: Anti-HIV Agents; Body Composition; Child; Child, Preschool; Cross-Sectional Studies; Drug Therapy, C | 2013 |
Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Blood Glucose; Body Composition; Bone Density; C-Peptide; Cy | 2004 |
Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine.
Topics: Adult; Alkynes; Anthropometry; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; | 2005 |
HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Composition; Carnitine; Dideox | 2001 |
5 other studies available for nevirapine and Insulin Resistance
| Article | Year |
|---|---|
Cardiometabolic risk factors among HIV patients on antiretroviral therapy.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxa | 2013 |
Morphological and metabolic components of lipodystrophy in various nevirapine-based highly active antiretroviral therapy (HAART) regimens: a cross-sectional, observational study.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Composition; Body Fat Dist | 2011 |
Serum adiponectin and metabolic parameters in HIV-1-infected patients after substitution of nevirapine for protease inhibitors.
Topics: Adiponectin; Adult; Anti-HIV Agents; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; | 2004 |
[Lipodystrophy and 'buffalo hump' during treatment with HIV protease inhibitors].
Topics: Adult; Cardiovascular Diseases; CD4 Lymphocyte Count; Diabetes Mellitus, Type 2; Drug Therapy, Combi | 1998 |
Transfer therapy--Nevirapine for protease problems?
Topics: Adipose Tissue; Anthropometry; Blood Glucose; CD4 Lymphocyte Count; Cholesterol; Drug Therapy, Combi | 1999 |